Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Common stock, par value $0.0001 per share
Symbol
ABOS on Nasdaq
Shares outstanding
60,660,421
Price per share
$2.11
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
35,732,361
Total reported value
$61,097,340
% of total 13F portfolios
0%
Share change
-1,855,545
Value change
-$2,856,744
Number of holders
68
Price from insider filings
$2.11
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 25% $16,517,669 15,016,063 RA Capital Management, L.P. 27 Mar 2025
Sands Capital Alternatives, LLC 5.6% $3,861,295 3,417,075 Sands Capital Alternatives, LLC 30 Jun 2025
FRANKLIN RESOURCES INC 3.8% $3,941,714 2,305,096 Franklin Resources, Inc. 30 Sep 2025

As of 30 Sep 2025, 68 institutional investors reported holding 35,732,361 shares of Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS). This represents 59% of the company’s total 60,660,421 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) together control 57% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 25% 14,932,063 0% 0.31% $25,533,828
Sands Capital Alternatives, LLC 5.6% 3,417,075 0% 1.3% $5,843,198
FRANKLIN RESOURCES INC 3.8% 2,305,096 -25% 0% $3,941,714
FMR LLC 3.3% 2,029,325 -0.02% 0% $3,470,146
VANGUARD GROUP INC 2.7% 1,651,472 -2.2% 0% $2,824,017
Knollwood Investment Advisory, LLC 2.7% 1,628,510 0% 0.25% $2,784,752
Alyeska Investment Group, L.P. 1.5% 939,603 0% 0% $1,606,721
ADAR1 Capital Management, LLC 1.5% 891,183 -2.7% 0.15% $1,523,923
Laurion Capital Management LP 1.4% 867,046 0% 0.2% $1,482,649
Pathstone Holdings, LLC 1.4% 859,110 -19% 0.01% $1,469,078
Hudson Bay Capital Management LP 1.2% 725,004 -12% 0.01% $1,239,757
MILLENNIUM MANAGEMENT LLC 0.99% 601,716 -69% 0% $1,028,934
RENAISSANCE TECHNOLOGIES LLC 0.96% 584,292 +137% 0% $999,139
CITADEL ADVISORS LLC 0.81% 494,108 0% $844,925
TWO SIGMA ADVISERS, LP 0.7% 423,600 -0.63% 0% $724,356
SG Americas Securities, LLC 0.67% 403,878 0% $691,000
GEODE CAPITAL MANAGEMENT, LLC 0.66% 398,778 +0.54% 0% $682,039
Ikarian Capital, LLC 0.44% 265,769 0% 0.1% $454,465
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.35% 214,440 +41% 0% $366,693
BANK OF AMERICA CORP /DE/ 0.35% 213,729 +45% 0% $365,477
JANE STREET GROUP, LLC 0.34% 207,239 +18% 0% $354,379
TWO SIGMA INVESTMENTS, LP 0.33% 199,446 -0.67% 0% $341,053
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.31% 190,171 +65% 0.01% $325,192
BlackRock, Inc. 0.29% 174,690 -40% 0% $298,719
MORGAN STANLEY 0.25% 149,401 -2.8% 0% $255,476

Institutional Holders of Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 402,626 $849,332 -$5,233 $2.11 3
2025 Q3 35,732,361 $61,097,340 -$2,856,744 $1.71 68
2025 Q2 37,585,884 $43,599,129 -$2,103,479 $1.16 69
2025 Q1 39,403,584 $43,344,870 -$3,628,850 $1.10 79
2024 Q4 42,499,401 $73,099,738 -$2,305,406 $1.72 78
2024 Q3 43,605,225 $107,681,203 -$212,803 $2.48 72
2024 Q2 43,581,156 $105,487,337 -$2,322,503 $2.42 81
2024 Q1 43,364,829 $175,565,762 +$20,042,386 $4.05 78
2023 Q4 38,441,008 $147,599,716 -$20,522,527 $3.84 67
2023 Q3 43,186,479 $179,213,677 +$71,103,757 $4.15 64
2023 Q2 26,328,948 $126,640,120 -$5,262,013 $4.81 52
2023 Q1 27,781,261 $112,787,020 -$4,579,764 $4.06 61
2022 Q4 28,727,743 $155,145,749 -$5,374,332 $5.40 59
2022 Q3 27,496,751 $275,793,298 +$19,526,193 $10.03 48
2022 Q2 25,628,401 $120,458,000 -$6,031,616 $4.70 44
2022 Q1 27,062,428 $105,815,702 -$3,031,020 $3.91 53
2021 Q4 25,569,796 $172,840,000 -$1,670,403 $6.76 50
2021 Q3 24,050,108 $357,352,000 +$306,574,000 $14.86 40